NeuroOne restates March-quarter results after $0.5 million revenue overstatement

• NeuroOne Medical Technologies will amend and restate its quarterly financial statements for the period ended March 31, 2026, replacing results filed May 12 in its Form 10-Q.
• The restatement addresses a revenue recognition error tied to a customer order modification on quarter-end shipments.
• Revenue was overstated by about $0.5 million versus the $2.4 million initially reported.
• Gross profit was overstated by about $0.3 million, while operating loss and net loss were understated by about $0.3 million.
• Product revenue guidance of at least $10.5 million for fiscal 2026 was reaffirmed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-060600), on May 22, 2026, and is solely responsible for the information contained therein.